Embera Neurotherapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.emberaneuro.com
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Study of EMB-001 as a Potential Smoking Cessation Treatment
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Embera NeuroTherapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04933916
- Locations
- 🇺🇸
Embera Site, Miami Lakes, Florida, United States
🇺🇸Rose Research Center, Raleigh, North Carolina, United States
A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Embera NeuroTherapeutics, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT04501874
- Locations
- 🇺🇸
Pacific Treatment and Research Center, Department of Psychiatry, University of California, San Diego, School of Medicine, San Diego, California, United States
🇺🇸Segal Trials, Miami, Florida, United States
🇺🇸U PENN- Perelman School of Medicine, Philadelphia, Pennsylvania, United States
Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations
- Conditions
- Cocaine Use Disorder
- Interventions
- Drug: Original formulation EMB-001Drug: New formulation EMB-001
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- Embera NeuroTherapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03404817
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States
A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine
- Conditions
- Cocaine Use Disorder
- Interventions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Embera NeuroTherapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02856854
- Locations
- 🇺🇸
Vince & Associates, Overland Park, Kansas, United States
Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)
- Conditions
- Tobacco Use DisorderCocaine Use Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2016-07-22
- Lead Sponsor
- Embera NeuroTherapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02406066
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States
🇺🇸Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
- Prev
- 1
- 2
- Next